Proactive’s Post

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: September 23 - 24, 2024 • Novartis’ $1B+ biobucks deal with Generate:Biomedicines • Capricor Therapeutics, Inc. stock explodes on cell therapy BLA filing intention • Biogen & UCB's two decade lupus struggle seemingly vindicated with a Ph3 win • Constructive Bio’s $58M Series A for cellular bio factories • Cell therapy CDMO Minaris Regenerative Medicine to be acquired by investment firm Altaris, LLC • Lonza signs on to manufacture Vertex Pharmaceuticals’s Casgevy CRISPR-based therapy • bluebird bio and AGC Biologics both announces layoffs • Baltimore sues Biogen over alleged PBM “bribes” to stifle MS generic competition More in today's TLDR Biotech newsletter: https://lnkd.in/gv5W2Z8V #biotech #pharma #pharmanews #biotechnews #tldrbiotech

📈 Big Moves in Biotech! Ono Pharmaceutical seals a transformative $2.4B deal, acquiring Deciphera Pharmaceuticals to revolutionize its cancer drug portfolio. 🎯 Ono bags an approved game-changer Qinlock, a potential blockbuster vimseltinib, and key commercial infrastructure to strengthen its US presence. Deciphera shareholders get a 70% premium windfall 💰 Despite global uncertainties, companies are moving ahead, innovating, and investing in treatments. This move signals strong confidence in the cancer therapy market's future.🧬 What are your thoughts on this strategic acquisition? #Biotech #CancerResearch #PharmaceuticalIndustry

Genentech and Adaptimmune - The $3B break up! 💔 In the same week that Genentech confirmed it's cutting 3% of its staff, the Roche subsidiary has terminated a cell therapy partnership with Adaptimmune. Genentech paid $150M to the deal in 2021 💸 and have paid an additional $35M in milestone payments since. For Adaptimmune, the termination comes almost exactly one year after another pharma discontinued work with the biotech. In April 2023, GSK paid Adaptimmune $37.3 million to wipe its hands of two programs, one of which included lete-cel, an asset the company at one point touted as its leading cell therapy. So, what do we think that means for the future of Adaptimmune? Could it be seen as positive? 🌟🧬 #Biotech #HealthcareInnovation #CellTherapy

Thoughts on this? >> Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

The covalency renaissance is heating up, as funding and collaboration fuel the development of chemoproteomic platforms and innovative modalities for hard-to-drug targets. December's 2nd Covalent Drug Discovery & Development Summit will reunite 100+ covalency specialists to deep dive into topics like: 🔹 Overcoming challenges in balancing reactivity and sensitivity with advanced screening cascades with Genentech, Scorpion Therapeutics, Amgen and Covant Therapeutics 🔹 Unlocking novel warheads for covalent screening of histidine, tyrosine and lysine residues to expand the druggable proteome with Hyku Biosciences, Bayer and Nexo Therapeutics 🔹 Exploring the advancing paradigm of covalent PROTACs and monovalents with the latest developments from Vividion Therapeutics, Inc., Baylor College of Medicine, Pfizer and Harvard University Download your copy of the program here: https://ter.li/76az03 #covalent #covalency #drugdiscovery #smallmolecule

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

🌱💡 Empowering Cancer Treatment's Future: Tissue Dynamics and OrganoSpheres Revolutionize Health with Organoid Robotics and AI! #EmpoweringCancerTreatment #OrganoidRobotics #AIInnovation #HealthRevolution #TissueDynamics #OrganoSpheres #FutureOfHealthcare #CuttingEdgeTech

Who is Alumis? What they are doing: The Cal-based biotech is coming out with an IPO to fund/advance several autoimmune programs, including an oral, TYK2-inh P3 program in #Psoriasis. #CompetitiveAspect: If its ESK-001 is "more selective; more potent"...could it eek ahead of Bristol Myers Squibb's #Sotyktu?? #Biotech #IPO #Pharma #Healthcare #Alumis Takeda Ventyx Biosciences #Alumis

In recent days, the Warsaw Stock Exchange (GPW) has been abuzz with remarkable activity in the #biotechnology sector, with several companies experiencing substantial gains. Here are the standout performers that have captured the attention of investors: 📊 Key Highlights: 1️⃣ Celon Pharma S.A. Sparks Biotech Rally: The #biotech mini-boom on the GPW began on July 8, triggered by positive clinical trial results from Celon Pharma. The company reported successful Phase II clinical trial results for its drug CPL'36 in treating acute schizophrenia. This announcement, followed by raised sales expectations from the company's CEO, propelled the stock by 89.09% over 13 sessions. Brokerage firms Trigon and Noble Securities S.A. further bolstered investor confidence by upgrading their recommendations for Celon Pharma. 2️⃣ NanoGroup S.A. Achieves Milestone in Organ Preservation: NanoGroup stole the spotlight with a groundbreaking announcement on July 17. A subsidiary of the company reported a successful pig kidney autotransplantation, validating its NanOX system for organ storage and perfusion. In the week following the announcement, NanoGroup's shares soared by 100%, and over the past month, they have surged by an impressive 180%. 3️⃣ Pure Biologics Advances Cancer Treatment Research: Pure Biologics has been another significant performer, driven by ongoing updates on its cancer treatment research and the entry of a new investor. From July 15, the company's shares have risen by 128%, providing investors with a 161% return over the past month. 4️⃣ Medinice S.A. Innovates in Cardiology: Medinice, a company specializing in medical devices for cardiology and cardiac surgery, has also seen notable gains. Since the previous Friday, its shares have climbed by over 30%, marking a 43.01% increase over the past month. 💡 Takeaway: These developments highlight the dynamic nature of the biotechnology sector on the GPW, driven by groundbreaking research and strategic advancements. Investors should stay tuned to these companies' progress as they continue to innovate and achieve new milestones. 📖 Explore the full articles for detailed information 👇 Maciej Wierzbicki, PhD, Joanna Sasin-Kurowska, Anna Nowak, Mikolaj Matloka, Ewelina Juszczyk, Ph.D., Wojciech Pietruś, Abda Yamani, Bartosz Szalek, Mikolaj Matloka, Artur Olender, Piotr Burliński, Paweł Wiśniewski, PhD, Filip Jelen, PhD, MBA, Ewelina Świderek, Pieter Spee, Grzegorz Wróblewski PhD, Marcin Gołębicki, Sanjeev Choudhary We'd love to hear your thoughts on these exciting developments and how your organization is gearing up for success in this thriving sector.

“Drug development is a high-risk, high-reward business, and the structure of a company can play a critical role in determining its success.” Our Chief Business Officer Abbas Kazimi broke down the advantages of adopting the limited liability company (LLC) structure in an ever-changing life sciences industry in a piece for Life Science Leader magazine. Abbas honed in on the ways Nimbus has executed and expanded under this model, leveraging its flexibility. Read the full article in Life Science Leader: https://bit.ly/4eCPxF0